Alnylam Pharmaceuticals, Inc. (ALNY)
USD 237.92
(-3.51%)
USD 237.92
(-3.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 104.15 Million | -541.27 Million | -641.69 Million | -614.96 Million | -278.42 Million | -562.61 Million |
| Net Income | -440.24 Million | -1.13 Billion | -852.82 Million | -858.28 Million | -886.11 Million | -761.49 Million |
| Depreciation & Amortization | 54.05 Million | 85.55 Million | 89.69 Million | 74.43 Million | 54.36 Million | 6.43 Million |
| Deferred income taxes | -399.36 Million | - | -55.69 Million | -54.04 Million | -11.28 Million | -3.56 Million |
| Stock-based compensation | 221.68 Million | 230.64 Million | 165.71 Million | 139.87 Million | 174.84 Million | 157.75 Million |
| Change in working capital | 10.75 Million | -35.55 Million | -162.82 Million | -12.7 Million | 402.38 Million | 45.09 Million |
| Other non-cash items | 657.26 Million | 309.23 Million | 174.23 Million | 95.75 Million | -12.61 Million | -6.84 Million |
| Investing Cash Flow | -336.35 Million | 169.35 Million | -273.3 Million | -435.51 Million | -417.67 Million | 272.94 Million |
| Investments in PPE | -62.21 Million | -72.05 Million | -76.37 Million | -70.36 Million | -140.15 Million | -126.88 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -1.88 Billion | -1.97 Billion | -1.65 Billion | -2.02 Billion | -2.07 Billion | -1.1 Billion |
| Sales/Maturities of investments | 1.61 Billion | 2.23 Billion | 1.46 Billion | 1.69 Billion | 1.77 Billion | 1.51 Billion |
| Other Investing Activities | -4.43 Million | -13.19 Million | -4.36 Million | -31.2 Million | 23 Million | -14.82 Million |
| Financing Cash Flow | 172.13 Million | 425.75 Million | 1.24 Billion | 994.97 Million | 823.18 Million | 65.47 Million |
| Debt repayment | - | -762.1 Million | -1 Billion | -686.59 Million | -30 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | -3.46 Million |
| Common Stock Issuance | 147.46 Million | 259.36 Million | 246.26 Million | 99.49 Million | 853.18 Million | 68.93 Million |
| Other Financing Activities | 24.66 Million | 928.5 Million | 2 Billion | 1.58 Billion | 823.18 Million | 68.93 Million |
| Accounts receivables | -87.93 Million | -45.59 Million | -101.79 Million | -56.23 Million | -24.23 Million | 15.24 Million |
| Accounts payables | 80.84 Million | 191.76 Million | 88.24 Million | 117.37 Million | 36.6 Million | 15.47 Million |
| Inventory | 18.36 Million | -34.13 Million | -26.41 Million | -35.42 Million | -32.41 Million | -22.64 Million |
| Other working capital | -509 Thousand | -147.58 Million | -122.84 Million | -38.41 Million | 422.42 Million | 37.02 Million |
| Cash at beginning of period | 866.39 Million | 822.15 Million | 499.04 Million | 549.62 Million | 422.63 Million | 646.83 Million |
| Cash at end of period | 812.68 Million | 868.55 Million | 822.15 Million | 499.04 Million | 549.62 Million | 422.63 Million |
| Capital Expenditure | -62.21 Million | -72.05 Million | -76.37 Million | -70.36 Million | -140.15 Million | -126.88 Million |
| Effect of forex changes on cash | 6.39 Million | -7.43 Million | -9.01 Million | 4.91 Million | -83 Thousand | - |
| Net cash flow / Change in cash | -53.7 Million | 46.4 Million | 323.1 Million | -50.58 Million | 126.99 Million | -224.2 Million |
| Free Cash Flow | 41.94 Million | -613.33 Million | -718.06 Million | -685.32 Million | -418.58 Million | -689.5 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -111.57 Million | -16.88 Million | -65.93 Million | -440.24 Million | -137.87 Million | 147.75 Million |
| Depreciation & Amortization | 48.69 Million | 15 Million | 13.51 Million | 54.05 Million | 13.48 Million | 23.53 Million |
| Deferred income taxes | - | - | - | -399.36 Million | -53.09 Million | 39.25 Million |
| Stock-based compensation | 45.8 Million | 89.28 Million | 45.34 Million | 221.68 Million | 41.99 Million | 63.93 Million |
| Change in working capital | 170.6 Million | -49.3 Million | -121.29 Million | 10.75 Million | 6.79 Million | 25.52 Million |
| Other non-cash items | -109.82 Million | 114.44 Million | 123.66 Million | 657.26 Million | 98.9 Million | 59.4 Million |
| Investing Cash Flow | -30.25 Million | 33.94 Million | -67.62 Million | -336.35 Million | -240.65 Million | -10.76 Million |
| Investments in PPE | -4.19 Million | -8.01 Million | -12.97 Million | -62.21 Million | -15.3 Million | -17.09 Million |
| Acquisitions | - | - | - | - | 225.34 Million | -10.76 Million |
| Investment purchases | -449.57 Million | -315.61 Million | -460.09 Million | -1.88 Billion | -589.15 Million | -421.45 Million |
| Sales/Maturities of investments | 365.64 Million | 357.56 Million | 405.44 Million | 1.61 Billion | 363.81 Million | 432.22 Million |
| Other Investing Activities | 57.87 Million | 41.95 Million | 39.97 Million | -4.43 Million | -225.34 Million | 6.32 Million |
| Financing Cash Flow | 102.75 Million | 131.49 Million | 28.91 Million | 172.13 Million | 39.22 Million | 33.13 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | -158.63 Million | 132.77 Million | 25.85 Million | 147.46 Million | 30.89 Million | 24.8 Million |
| Other Financing Activities | 261.39 Million | -1.28 Million | 3.05 Million | 24.66 Million | 8.33 Million | 8.33 Million |
| Accounts receivables | -37.09 Million | 9.64 Million | 410 Thousand | -87.93 Million | 3.86 Million | -107.99 Million |
| Accounts payables | 83.59 Million | 74.47 Million | -4.86 Million | 80.84 Million | -38.66 Million | 118.74 Million |
| Inventory | 5.92 Million | 6.79 Million | 22 Thousand | 18.36 Million | 11.99 Million | 4.79 Million |
| Other working capital | 257.07 Million | -140.2 Million | -116.86 Million | -509 Thousand | 29.59 Million | 9.98 Million |
| Cash at beginning of period | 968.49 Million | 681.87 Million | 812.68 Million | 866.39 Million | 1.03 Billion | 659.97 Million |
| Cash at end of period | 1.1 Billion | 968.49 Million | 681.87 Million | 812.68 Million | 812.68 Million | 1.03 Billion |
| Capital Expenditure | -4.19 Million | -8.01 Million | -12.97 Million | -62.21 Million | -15.3 Million | -17.09 Million |
| Effect of forex changes on cash | 15.09 Million | -3.12 Million | -9.94 Million | 6.39 Million | 10.89 Million | -6.55 Million |
| Net cash flow / Change in cash | 134 Million | 286.61 Million | -130.8 Million | -53.7 Million | -220.33 Million | 375.23 Million |
| Free Cash Flow | 39.51 Million | 116.14 Million | -94.48 Million | 41.94 Million | -45.1 Million | 342.32 Million |
ESR
603118
PBM
6740
03473K
GIPCL